Abstract
Background: Pancreatic lipase is one of the safest targets of anti-obesity drugs. To date, orlistat is the only pancreatic lipase inhibitor approved for the long-term treatment of obesity. Therefore, there is an elevated need to find new drugs for this disease. Determining the factors affecting the test to evaluate pancreatic lipase inhibitory activity in order to build a standard assay procedure is necessary. This will make it much easier for researchers to find novel compounds that inhibit the enzyme. Materials and method: The current study investigated the factors influencing pancreatic lipase activity and evaluated the enzyme inhibition of orlistat by spectrophotometric method at 405 nm using p-nitrophenyl palmitate as a substrate. Results: With the optimized conditions, the test to evaluate pancreatic lipase inhibitory activity of orlistat gave results similar to those published by other authors. Conclusion: The methodology of this work should be applied in the studies looking for new effective drugs to treat obesity. Key words: obesity, orlistat.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
